10x Genomics, Inc. (TXG): Results of Operations and Financial Condition
10x Genomics, Inc. (TXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 txg-20260806xexx991.htm EX-99.1 Document Exhibit 99.1 10x Genomics Reports Second Quarter 2026 Financial Results PLEASANTON, Calif. August 6, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human
How this was made
The 30-second read
Why it matters
The key tradable datapoint is the raised full-year revenue range, supported by higher gross margin and commentary on early order flow for Atera. Offsetting factors include higher operating expenses and a net loss vs the prior-year quarter, with several line items attributed to non-recurring patent settlement effects.
Market read
A guidance raise with specific revenue range and supporting margin/cash details makes this a direct catalyst for TXG positioning into and after the earnings call.
What to watch
Tariff refunds and lower inventory write-downs boosted gross margin; traders may watch whether those benefits are repeatable in subsequent quarters, and whether operating expenses re-accelerate once settlement gains/losses normalize.
Background
This is an SEC 8-K (Item 2.02) with the company’s Q2 2026 financial results and updated full-year 2026 revenue guidance, plus business updates (acquisition and research collaborations).
Ticker impact
10x Genomics reported Q2 2026 results and raised full-year 2026 revenue guidance to $610M-$630M from $600M-$625M.
Bias toward upside on the guidance raise, with follow-through dependent on whether investors focus on revenue growth vs the operating loss and settlement-driven comparables.
The filing discloses a specific, time-sensitive guidance update and multiple operating metrics (gross margin, operating loss, cash). However, revenue is down year over year on a reported basis and operating loss widened, with several items explicitly tied to non-recurring settlement effects, which can temper the reaction.
Market effects
Signals demand resilience in single-cell and spatial workflows (Atera order flow) and continued investment in diagnostics collaborations, which can influence sentiment across life-science tools and multiomics peers.
Limited direct regional spillover; primarily affects US-listed biotech/life-science instrumentation sentiment.
Moderate global relevance via multi-year collaborations (Cleveland Clinic, Lausanne University Hospital) and acquisition strengthening multiomics capabilities.
Counterpoint
Investors may discount the guidance raise if they view it as normalization after settlement-related revenue and expense swings, given reported revenue and operating income both deteriorated year over year.
Key entities
- public_company10x Genomics, Inc.
Nasdaq-listed life science technology company; reported Q2 2026 results and raised FY 2026 revenue guidance.
- product_or_platformAtera
Company cited “extraordinary customer response” and “very strong early order flow” during the quarter.
- acquisition_targetProteintech Genomics (division within Proteintech Group)
10x Genomics acquired Proteintech Genomics to add advanced protein detection capabilities to its multiomics strategy.
- research_partnerCleveland Clinic
Announced multi-year research collaboration to advance diagnostic applications of single cell and spatial technologies for cancer care.
- research_partnerLausanne University Hospital
Announced multi-year research collaboration to advance diagnostic applications of single cell and spatial technologies for cancer care.
